Gale Smith

16.5k total citations · 4 hit papers
115 papers, 10.7k citations indexed

About

Gale Smith is a scholar working on Molecular Biology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Gale Smith has authored 115 papers receiving a total of 10.7k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Molecular Biology, 50 papers in Epidemiology and 45 papers in Infectious Diseases. Recurrent topics in Gale Smith's work include Viral Infectious Diseases and Gene Expression in Insects (35 papers), Respiratory viral infections research (30 papers) and Influenza Virus Research Studies (23 papers). Gale Smith is often cited by papers focused on Viral Infectious Diseases and Gene Expression in Insects (35 papers), Respiratory viral infections research (30 papers) and Influenza Virus Research Studies (23 papers). Gale Smith collaborates with scholars based in United States, Netherlands and China. Gale Smith's co-authors include Max D. Summers, Malcolm J. Fraser, M D Summers, Gregory M. Glenn, Just M. Vlak, Michael J. Massare, David C. Flyer, Peter Pushko, Terrence M. Tumpey and Louis Fries and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Gale Smith

110 papers receiving 9.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures.

1987 1.5k citations Gale Smith et al. profile →
Production of human beta interferon in insect cells infected with a baculovirus expression vector.

1983 721 citations Gale Smith et al. profile →
The bidirectional transfer of DNA and RNA to nitrocellulose or diazobenzyloxymethyl-paper

1980 706 citations Gale Smith et al. profile →
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

2021 222 citations Gale Smith, Gregory M. Glenn et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gale Smith United States	57	6.1k	2.7k	2.7k	1.8k	1.4k	115	10.7k
Paul Ahlquist United States	73	5.1k 0.8×	1.9k 0.7×	1.7k 0.6×	952 0.5×	783 0.6×	176	14.7k
Ian M. Jones United Kingdom	51	3.3k 0.5×	1.7k 0.6×	1.7k 0.7×	1.7k 0.9×	1.1k 0.8×	177	8.1k
Robert Ménard France	61	3.9k 0.6×	1.4k 0.5×	1.4k 0.5×	2.6k 1.4×	1.1k 0.8×	180	11.8k
Dyann F. Wirth United States	63	3.6k 0.6×	1.6k 0.6×	2.4k 0.9×	1.6k 0.9×	837 0.6×	253	11.8k
Leevi Kääriäinen Finland	58	2.2k 0.4×	3.7k 1.4×	1.9k 0.7×	883 0.5×	816 0.6×	152	8.3k
Daved H. Fremont United States	75	3.6k 0.6×	7.2k 2.7×	2.9k 1.1×	6.9k 3.8×	936 0.7×	218	17.7k
Raul Andino United States	62	6.5k 1.1×	4.9k 1.8×	2.2k 0.8×	2.0k 1.1×	2.8k 2.1×	142	15.0k
Henrik Garoff Sweden	54	3.2k 0.5×	3.7k 1.4×	2.3k 0.9×	1.2k 0.7×	1.5k 1.1×	130	9.2k
David C. Kaslow United States	63	3.0k 0.5×	1.2k 0.4×	2.0k 0.7×	4.2k 2.3×	559 0.4×	217	10.8k
Akio Nomoto Japan	56	4.8k 0.8×	3.2k 1.2×	2.1k 0.8×	1.1k 0.6×	1.3k 1.0×	176	10.6k

Countries citing papers authored by Gale Smith

Since Specialization

Citations

This map shows the geographic impact of Gale Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gale Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gale Smith more than expected).

Fields of papers citing papers by Gale Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gale Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gale Smith. The network helps show where Gale Smith may publish in the future.

Co-authorship network of co-authors of Gale Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Gale Smith. A scholar is included among the top collaborators of Gale Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gale Smith. Gale Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patel, Nita, Rhonda Flores, Mimi Guebre‐Xabier, et al.. (2025). Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin–Matrix-M® nanoparticle vaccine induces neutralizing responses in nonhuman primates. Nature Communications. 16(1). 6625–6625.

Bangaru, Sandhya, Abigail M. Jackson, Jeffrey Copps, et al.. (2025). Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines. Cell Reports. 44(7). 115986–115986.

Sachithanandham, Jaiprasath, Jennifer A. Liu, Patrick S. Creisher, et al.. (2025). COVID-19 vaccine (NVX-CoV2373 and NVX-CoV2540) doses and virus strain match impact sex- and age-specific immunity and protection in mice. Vaccine. 61. 127409–127409.

Bricker, Traci L., Astha Joshi, Nadia Soudani, et al.. (2024). Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters. Journal of Virology. 98(3). e0120623–e0120623. 4 indexed citations

Johnson, Robert M., Holly Hammond, James Logue, et al.. (2023). Diet-induced obesity and diabetes enhance mortality and reduce vaccine efficacy for SARS-CoV-2. Journal of Virology. 97(11). e0133623–e0133623. 9 indexed citations

Stertman, Linda, Anna-Karin E. Palm, Berit Carow, et al.. (2023). The Matrix-M™ adjuvant: A critical component of vaccines for the 21 ^st century. Human Vaccines & Immunotherapeutics. 19(1). 2189885–2189885. 59 indexed citations

Wilkinson, Bethanie, Katherine R. Smith, Robert Walker, et al.. (2023). A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses. Vaccine. 41(45). 6762–6773. 2 indexed citations

Levine, Min Z., Crystal Holiday, Yaohui Bai, et al.. (2022). Influenza A(H7N9) Pandemic Preparedness: Assessment of the Breadth of Heterologous Antibody Responses to Emerging Viruses from Multiple Pre-Pandemic Vaccines and Population Immunity. Vaccines. 10(11). 1856–1856. 6 indexed citations

Shinde, Vivek, Rongman Cai, Joyce S. Plested, et al.. (2020). Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M–Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine. Clinical Infectious Diseases. 73(11). e4278–e4287. 20 indexed citations

10.

Bangaru, Sandhya, Gabriel Ozorowski, Hannah L. Turner, et al.. (2020). Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science. 370(6520). 1089–1094. 228 indexed citations

11.

Patel, Nita, Jing-Hui Tian, Mimi Guebre‐Xabier, et al.. (2019). Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection. Vaccine. 37(41). 6112–6124. 28 indexed citations

12.

Tian, Jing-Hui, Gregory M. Glenn, David C. Flyer, et al.. (2017). Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models. Vaccine. 35(33). 4079–4087. 13 indexed citations

13.

Glenn, Gregory M., Louis Fries, D. Nigel Thomas, et al.. (2015). A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age. The Journal of Infectious Diseases. 213(3). 411–422. 115 indexed citations

14.

Coleman, Christopher M., Ye V. Liu, Justin Taylor, et al.. (2014). Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine. 32(26). 3169–3174. 226 indexed citations

15.

Glenn, Gregory M., Gale Smith, Louis Fries, et al.. (2012). Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine. 31(3). 524–532. 108 indexed citations

16.

Lambert, John S., James McNamara, Samuel L. Katz, et al.. (1998). Safety and Immunogenicity of HIV Recombinant Envelope Vaccines in HIV-Infected Infants and Children. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 19(5). 451–461. 25 indexed citations

17.

Keefer, Michael C., Barney S. Graham, Robert B. Belshe, et al.. (1994). Studies of High Doses of a Human Immunodeficiency Virus Type 1 Recombinant Glycoprotein 160 Candidate Vaccine in HIV Type 1-Seronegative Humans. AIDS Research and Human Retroviruses. 10(12). 1713–1723. 46 indexed citations

18.

Graham, Barney S., Geoffrey J. Gorse, David H. Schwartz, et al.. (1994). Determinants Of Antibody Response After Recombinant Gp160 Boosting In Vaccinia-Naive Volunteers Primed With Gp160-Recombinant Vaccinia Virus. The Journal of Infectious Diseases. 170(4). 782–786. 29 indexed citations

19.

Kovacs, Joseph A., M. B. Vasudevachari, Richard T. Davey, et al.. (1993). Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.. Journal of Clinical Investigation. 92(2). 919–928. 32 indexed citations

20.

Berkower, Ira, et al.. (1989). Human immunodeficiency virus 1. Predominance of a group-specific neutralizing epitope that persists despite genetic variation.. The Journal of Experimental Medicine. 170(5). 1681–1695. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact